Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …
genomic landscapes and biological functions, the treatment of PCa continues to improve …
Genetics and biology of prostate cancer
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways
Y Zhang, F Chen, DS Chandrashekar… - Nature …, 2022 - nature.com
Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression
Prostate cancer shows remarkable clinical heterogeneity, which manifests in spatial and
clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is …
clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is …
Biologically informed deep neural network for prostate cancer discovery
The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
The DNA methylation landscape of advanced prostate cancer
Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …
methylation landscape of metastatic cancer has never been defined. Through whole …
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross… - Nature Cancer, 2022 - nature.com
Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …
Molecular landmarks of tumor hypoxia across cancer types
Many primary-tumor subregions have low levels of molecular oxygen, termed hypoxia.
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …
[HTML][HTML] Genomic hallmarks and structural variation in metastatic prostate cancer
While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …
cancers, structural variants at the genome-wide level are still poorly defined. Through …
The long tail of oncogenic drivers in prostate cancer
Comprehensive genomic characterization of prostate cancer has identified recurrent
alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among …
alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among …